NASDAQ:PSTV Plus Therapeutics (PSTV) Stock Price, News & Analysis → How to Play the AI and Crypto Markets in One Swing (From Weiss Ratings) (Ad) Free PSTV Stock Alerts $2.12 -0.05 (-2.30%) (As of 08:58 AM ET) Add Compare Share Share Today's Range$2.12▼$2.1250-Day Range$1.60▼$2.2752-Week Range$0.97▼$4.45Volume473 shsAverage Volume56,050 shsMarket Capitalization$9.07 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Plus Therapeutics alerts: Email Address Plus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside277.4% Upside$8.00 Price TargetShort InterestHealthy1.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 11 Articles This WeekInsider TradingAcquiring Shares$55,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.99) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPlus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePlus Therapeutics has received no research coverage in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.10% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Plus Therapeutics has recently decreased by 0.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PSTV. Previous Next 3.1 News and Social Media Coverage News SentimentPlus Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Plus Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for PSTV on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.32% of the stock of Plus Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Plus Therapeutics are expected to decrease in the coming year, from ($0.99) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Plus Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Plus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsTiny AI projects with huge promise hiding in plain sight …I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.Click here to find out who they are. About Plus Therapeutics Stock (NASDAQ:PSTV)Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Read More PSTV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSTV Stock News HeadlinesMay 11, 2024 | insidertrades.comAndrew John Hugh Macintyr Sims Acquires 4,902 Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) StockMay 13 at 7:32 AM | americanbankingnews.comInsider Buying: Plus Therapeutics, Inc. (NASDAQ:PSTV) CEO Purchases $25,000.20 in StockMay 13 at 7:30 AM | globenewswire.comPlus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024May 12 at 6:55 PM | uk.investing.comPlus Therapeutics CEO buys $25,000 in company stockMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)May 9, 2024 | globenewswire.comPlus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE TrialMay 8, 2024 | globenewswire.comPlus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE TrialApril 22, 2024 | finance.yahoo.comMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseApril 22, 2024 | globenewswire.comPlus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefenseApril 19, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (PSTV)April 9, 2024 | finance.yahoo.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamApril 9, 2024 | globenewswire.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.March 27, 2024 | finance.yahoo.comPlus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferenceMarch 25, 2024 | finance.yahoo.comPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticMarch 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsMarch 11, 2024 | finance.yahoo.comPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesMarch 7, 2024 | finance.yahoo.comPlus Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 7, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | finance.yahoo.comQ4 2023 Plus Therapeutics Inc Earnings CallMarch 5, 2024 | investorplace.comPSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023March 5, 2024 | globenewswire.comPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsFebruary 29, 2024 | msn.comIMUNON stock rallies 19% on early results for COVID-19 vaccineFebruary 27, 2024 | finance.yahoo.comPlus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024February 21, 2024 | morningstar.comPlus Therapeutics Inc PSTVDecember 18, 2023 | finanznachrichten.dePlus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024See More Headlines Receive PSTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/15/2024Next Earnings (Confirmed)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PSTV CUSIPN/A CIK1095981 Webwww.plustherapeutics.com Phone737-255-7194Fax858-450-4335Employees20Year Founded1996Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+277.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($33.7590) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,320,000.00 Net Margins-271.04% Pretax Margin-271.04% Return on Equity-805.57% Return on Assets-97.73% Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.92 Sales & Book Value Annual Sales$4.91 million Price / Sales1.85 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-7.07Miscellaneous Outstanding Shares4,280,000Free Float4,177,000Market Cap$9.07 million OptionableNot Optionable Beta0.55 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Marc H. Hedrick M.B.A. (Age 61)M.D., President, CEO & Director Comp: $945.34kMr. Andrew J. Sims CPA (Age 51)VP of Finance & CFO Comp: $498.51kDr. Norman D. LaFrance FACNP (Age 76)FACP, M.D., Chief Medical Officer & Senior VP Comp: $646.02kMs. Desiree Smith (Age 60)Corporate Controller, Principal Financial & Accounting Officer Dr. John K. Fraser (Age 63)Chief Scientist Key CompetitorsNeuroMetrixNASDAQ:NUROBiotricityNASDAQ:BTCYProSomnusNASDAQ:OSAIntelligent Bio SolutionsNASDAQ:INBSVivos TherapeuticsNASDAQ:VVOSView All CompetitorsInsidersHoward ClowesBought 9,804 shares on 5/8/2024Total: $20,000.16 ($2.04/share)Marc H HedrickBought 12,255 shares on 5/8/2024Total: $25,000.20 ($2.04/share)Andrew John Hugh Macintyr SimsBought 4,902 shares on 5/8/2024Total: $10,000.08 ($2.04/share)Marc H HedrickSold 2,068 sharesTotal: $4,053.28 ($1.96/share)Robert P LenkBought 1,000 shares on 11/15/2023Total: $1,770.00 ($1.77/share)View All Insider Transactions PSTV Stock Analysis - Frequently Asked Questions Should I buy or sell Plus Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSTV shares. View PSTV analyst ratings or view top-rated stocks. What is Plus Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 1 year target prices for Plus Therapeutics' shares. Their PSTV share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 277.4% from the stock's current price. View analysts price targets for PSTV or view top-rated stocks among Wall Street analysts. How have PSTV shares performed in 2024? Plus Therapeutics' stock was trading at $1.7501 at the start of the year. Since then, PSTV shares have increased by 21.1% and is now trading at $2.12. View the best growth stocks for 2024 here. When is Plus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our PSTV earnings forecast. How can I listen to Plus Therapeutics' earnings call? Plus Therapeutics will be holding an earnings conference call on Wednesday, May 15th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:PSTV) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.08. The firm earned $1.31 million during the quarter, compared to analyst estimates of $1.26 million. Plus Therapeutics had a negative net margin of 271.04% and a negative trailing twelve-month return on equity of 805.57%. When did Plus Therapeutics' stock split? Shares of Plus Therapeutics reverse split before market open on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Plus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY). How do I buy shares of Plus Therapeutics? Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PSTV) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldBiden to Drop BOMBSHELL June 13th?Paradigm PressForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishingis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
